Up to 40% off at Dossier May 2024 Sale ...

OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update Financial and business highlights ...

A novel study by researchers at the Icahn School of Medicine at Mount Sinai addresses a critical yet under-explored question in cancer research: Why is aging the biggest risk factor for cancer ...

Repare ended June with $208.1 million in cash and equivalents, which it had estimated would fund its operations until at least mid-2026. The savings outlined in the Aug. 28 release are expected to ...

The "Thyroid Cancer - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering. The latest analytical report reveals a dynamic environment in the developmental landscape of ...

A new preclinical model using CRISPR, an advanced technology that allows scientists to cut and edit genes, has given Weill Cornell Medicine researchers and their colleagues a deeper insight into ...

So, how do you trade during premarket hours? You start by: Ensure that the trade you wish to make is allowed by your broker Determine how many shares you want to buy or sell — using your budget ...

This present study was designed to characterize the antitumor activity of saruparib in PDX models and compare efficacy in terms of preclinical complete response rate with the first-generation ...

The Dallas, Texas-based biotech said it plans to submit a dossier to the FDA later this year after its MCO-010 (sonpiretigene isteparvovec) gene therapy achieved almost all its primary and ...

Provention resubmitted its dossier in March with data on a modified 14-day treatment course, designed to match the exposure to the drug that was seen with the clinical trial material in earlier ...